Zobrazeno 1 - 10
of 432
pro vyhledávání: '"E. Lamoureux"'
Autor:
E. Lamoureux, M. G. Pagé
Publikováno v:
Canadian Journal of Pain, Vol 8, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/3de65bd1b62e46aeab6f204b3679f957
Autor:
Fiona Taylor, Cem Akin, Roger E. Lamoureux, Brad Padilla, Tanya Green, Anthony L. Boral, Iyar Mazar, Brenton Mar, Alan L. Shields, Frank Siebenhaar
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Abstract Background Advanced systemic mastocytosis (AdvSM), indolent systemic mastocytosis (ISM), and smoldering systemic mastocytosis (SSM) are rare diseases characterized by neoplastic mast cell infiltration of more than one organ. A content-valid
Externí odkaz:
https://doaj.org/article/e7491e39c049481e9d007aca4e635049
Autor:
Jane Loftus, Andrew Yaworsky, Carl L Roland, Diane Turner-Bowker, Megan McLafferty, Sylvia Su, Roger E Lamoureux
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0278293 (2022)
BackgroundDaily injections of recombinant human growth hormone are the standard of care to treat growth failure due to pediatric growth hormone deficiency (GHD). While effective, daily injections are burdensome and can compromise adherence. In recent
Externí odkaz:
https://doaj.org/article/49c3dccce5c54f34af8051c9443f1e9a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Meaghan Krohe, Yanni Hao, Roger E. Lamoureux, Nina Galipeau, Denise Globe, Catherine Foley, Iyar Mazar, Jeffrey Solomon, Alan L. Shields
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2016, Iss 10, Pp 93-102 (2016)
Externí odkaz:
https://doaj.org/article/81a2de5e6d694135a6b56673a232b746
Autor:
Alan L. Shields, Fiona Taylor, Roger E. Lamoureux, Brad Padilla, Kas Severson, Tanya Green, Anthony L. Boral, Cem Akin, Frank Siebenhaar, Brenton Mar
Publikováno v:
Orphanet Journal of Rare Diseases. 18
Background The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) (©Blueprint Medicines Corporation), a 12-item daily diary that assesses 11 signs and symptoms of indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bff6068d8a48d766faacb2388cddf45
https://doi.org/10.1186/s13023-023-02661-1
https://doi.org/10.1186/s13023-023-02661-1
Autor:
Roger E. Lamoureux, Fiona Taylor, Alan L. Shields, Anthony L. Boral, Iyar Mazar, Brad Padilla, Cem Akin, Brenton G. Mar, Tanya Green, Frank Siebenhaar
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases
Background Advanced systemic mastocytosis (AdvSM), indolent systemic mastocytosis (ISM), and smoldering systemic mastocytosis (SSM) are rare diseases characterized by neoplastic mast cell infiltration of more than one organ. A content-valid patient-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de84d49bc8ddd4bb1feb11a507badce
https://doaj.org/article/e7491e39c049481e9d007aca4e635049
https://doaj.org/article/e7491e39c049481e9d007aca4e635049
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrew E. Mulberg, Alan L. Shields, Vivian Kessler, Nina Skuban, Jay A. Barth, Fiona Taylor, Roger E. Lamoureux
Publikováno v:
Quality of Life Research
Purpose Fabry disease is a rare multisystemic disorder caused by functional deficiency of the lysosomal enzyme alpha-galactosidase A. Gastrointestinal (GI) signs and symptoms are among the earliest clinical manifestations in patients with Fabry disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbbb77d88c3b8ff9df1ed40f9a8e7799
https://doi.org/10.1007/s11136-021-02847-9
https://doi.org/10.1007/s11136-021-02847-9
Publikováno v:
Current Pediatric Reviews. 16:232-240
Background: Best practices for pediatric clinical outcomes assessment (COA) development rely on guidelines that have been developed for adult populations. While some useful resources are available to support pediatric COA development, this informatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e82aa6621251b59f45b4a47eb4a6b2
https://doi.org/10.2174/1573396316666200331132259
https://doi.org/10.2174/1573396316666200331132259